English
简体中文
Total: £ 56.28
Published Date: 2024-12-06 | Pages: 109 | Tables: 181 | Medical Care
Molecular cancer therapeutics focuses on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology.
The global market for Molecular Cancer Therapeutics was estimated to be worth US$ 139 million in 2023 and is forecast to a readjusted size of US$ 261.5 million by 2030 with a CAGR of 10.2% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Molecular Cancer Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Molecular Cancer Therapeutics by region & country, by Type, and by Application.
The Molecular Cancer Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Cancer Therapeutics.
Market Segmentation
By Company
Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
Segment by Type:
Monoclonal Antibodies
Small Molecule Inhibitors
Segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Molecular Cancer Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Molecular Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Molecular Cancer Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Molecular Cancer Therapeutics Product Introduction
1.2 Global Molecular Cancer Therapeutics Market Size Forecast
1.3 Molecular Cancer Therapeutics Market Trends & Drivers
1.3.1 Molecular Cancer Therapeutics Industry Trends
1.3.2 Molecular Cancer Therapeutics Market Drivers & Opportunity
1.3.3 Molecular Cancer Therapeutics Market Challenges
1.3.4 Molecular Cancer Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Molecular Cancer Therapeutics Players Revenue Ranking (2023)
2.2 Global Molecular Cancer Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Molecular Cancer Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Molecular Cancer Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Molecular Cancer Therapeutics
2.6 Molecular Cancer Therapeutics Market Competitive Analysis
2.6.1 Molecular Cancer Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Molecular Cancer Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Cancer Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monoclonal Antibodies
3.1.2 Small Molecule Inhibitors
3.2 Global Molecular Cancer Therapeutics Sales Value by Type
3.2.1 Global Molecular Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Molecular Cancer Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Molecular Cancer Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Lung Cancer
4.1.2 Breast Cancer
4.1.3 Colorectal Cancer
4.1.4 Leukemia
4.1.5 Others
4.2 Global Molecular Cancer Therapeutics Sales Value by Application
4.2.1 Global Molecular Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Molecular Cancer Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Molecular Cancer Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Molecular Cancer Therapeutics Sales Value by Region
5.1.1 Global Molecular Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Molecular Cancer Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Molecular Cancer Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Molecular Cancer Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Molecular Cancer Therapeutics Sales Value, 2019-2030
5.2.2 North America Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Molecular Cancer Therapeutics Sales Value, 2019-2030
5.3.2 Europe Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Molecular Cancer Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Molecular Cancer Therapeutics Sales Value, 2019-2030
5.5.2 South America Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Molecular Cancer Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Molecular Cancer Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Molecular Cancer Therapeutics Sales Value
6.3 United States
6.3.1 United States Molecular Cancer Therapeutics Sales Value, 2019-2030
6.3.2 United States Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Molecular Cancer Therapeutics Sales Value, 2019-2030
6.4.2 Europe Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Molecular Cancer Therapeutics Sales Value, 2019-2030
6.5.2 China Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Molecular Cancer Therapeutics Sales Value, 2019-2030
6.6.2 Japan Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Molecular Cancer Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Molecular Cancer Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Molecular Cancer Therapeutics Sales Value, 2019-2030
6.9.2 India Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Molecular Cancer Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Phoenix Molecular Designs
7.1.1 Phoenix Molecular Designs Profile
7.1.2 Phoenix Molecular Designs Main Business
7.1.3 Phoenix Molecular Designs Molecular Cancer Therapeutics Products, Services and Solutions
7.1.4 Phoenix Molecular Designs Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 Phoenix Molecular Designs Recent Developments
7.2 Prelude Therapeutics
7.2.1 Prelude Therapeutics Profile
7.2.2 Prelude Therapeutics Main Business
7.2.3 Prelude Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
7.2.4 Prelude Therapeutics Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Prelude Therapeutics Recent Developments
7.3 Tempus
7.3.1 Tempus Profile
7.3.2 Tempus Main Business
7.3.3 Tempus Molecular Cancer Therapeutics Products, Services and Solutions
7.3.4 Tempus Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Bracco Recent Developments
7.4 Bracco
7.4.1 Bracco Profile
7.4.2 Bracco Main Business
7.4.3 Bracco Molecular Cancer Therapeutics Products, Services and Solutions
7.4.4 Bracco Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Bracco Recent Developments
7.5 iOmx Therapeutics
7.5.1 iOmx Therapeutics Profile
7.5.2 iOmx Therapeutics Main Business
7.5.3 iOmx Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
7.5.4 iOmx Therapeutics Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 iOmx Therapeutics Recent Developments
7.6 OncoDNA
7.6.1 OncoDNA Profile
7.6.2 OncoDNA Main Business
7.6.3 OncoDNA Molecular Cancer Therapeutics Products, Services and Solutions
7.6.4 OncoDNA Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 OncoDNA Recent Developments
7.7 Sapience Therapeutics
7.7.1 Sapience Therapeutics Profile
7.7.2 Sapience Therapeutics Main Business
7.7.3 Sapience Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
7.7.4 Sapience Therapeutics Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Sapience Therapeutics Recent Developments
7.8 Caris Life Sciences
7.8.1 Caris Life Sciences Profile
7.8.2 Caris Life Sciences Main Business
7.8.3 Caris Life Sciences Molecular Cancer Therapeutics Products, Services and Solutions
7.8.4 Caris Life Sciences Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Caris Life Sciences Recent Developments
7.9 Hera Biolabs
7.9.1 Hera Biolabs Profile
7.9.2 Hera Biolabs Main Business
7.9.3 Hera Biolabs Molecular Cancer Therapeutics Products, Services and Solutions
7.9.4 Hera Biolabs Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 Hera Biolabs Recent Developments
7.10 CV6 Therapeutics
7.10.1 CV6 Therapeutics Profile
7.10.2 CV6 Therapeutics Main Business
7.10.3 CV6 Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
7.10.4 CV6 Therapeutics Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 CV6 Therapeutics Recent Developments
7.11 Carrick Therapeutics
7.11.1 Carrick Therapeutics Profile
7.11.2 Carrick Therapeutics Main Business
7.11.3 Carrick Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
7.11.4 Carrick Therapeutics Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 Carrick Therapeutics Recent Developments
7.12 Foundation Medicine
7.12.1 Foundation Medicine Profile
7.12.2 Foundation Medicine Main Business
7.12.3 Foundation Medicine Molecular Cancer Therapeutics Products, Services and Solutions
7.12.4 Foundation Medicine Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 Foundation Medicine Recent Developments
7.13 Cybrexa Therapeutics
7.13.1 Cybrexa Therapeutics Profile
7.13.2 Cybrexa Therapeutics Main Business
7.13.3 Cybrexa Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
7.13.4 Cybrexa Therapeutics Molecular Cancer Therapeutics Revenue (US$ Million) & (2019-2024)
7.13.5 Cybrexa Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Molecular Cancer Therapeutics Industrial Chain
8.2 Molecular Cancer Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Molecular Cancer Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Molecular Cancer Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Molecular Cancer Therapeutics Market Trends
Table 2. Molecular Cancer Therapeutics Market Drivers & Opportunity
Table 3. Molecular Cancer Therapeutics Market Challenges
Table 4. Molecular Cancer Therapeutics Market Restraints
Table 5. Global Molecular Cancer Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Molecular Cancer Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Molecular Cancer Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Molecular Cancer Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Molecular Cancer Therapeutics
Table 10. Global Molecular Cancer Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Cancer Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Molecular Cancer Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Molecular Cancer Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Molecular Cancer Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Molecular Cancer Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Molecular Cancer Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Molecular Cancer Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Molecular Cancer Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Molecular Cancer Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Molecular Cancer Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Molecular Cancer Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Molecular Cancer Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Molecular Cancer Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Molecular Cancer Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Molecular Cancer Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Molecular Cancer Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Molecular Cancer Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Molecular Cancer Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Molecular Cancer Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. Phoenix Molecular Designs Basic Information List
Table 32. Phoenix Molecular Designs Description and Business Overview
Table 33. Phoenix Molecular Designs Molecular Cancer Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Phoenix Molecular Designs (2019-2024)
Table 35. Phoenix Molecular Designs Recent Developments
Table 36. Prelude Therapeutics Basic Information List
Table 37. Prelude Therapeutics Description and Business Overview
Table 38. Prelude Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Prelude Therapeutics (2019-2024)
Table 40. Prelude Therapeutics Recent Developments
Table 41. Tempus Basic Information List
Table 42. Tempus Description and Business Overview
Table 43. Tempus Molecular Cancer Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Tempus (2019-2024)
Table 45. Tempus Recent Developments
Table 46. Bracco Basic Information List
Table 47. Bracco Description and Business Overview
Table 48. Bracco Molecular Cancer Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Bracco (2019-2024)
Table 50. Bracco Recent Developments
Table 51. iOmx Therapeutics Basic Information List
Table 52. iOmx Therapeutics Description and Business Overview
Table 53. iOmx Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of iOmx Therapeutics (2019-2024)
Table 55. iOmx Therapeutics Recent Developments
Table 56. OncoDNA Basic Information List
Table 57. OncoDNA Description and Business Overview
Table 58. OncoDNA Molecular Cancer Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of OncoDNA (2019-2024)
Table 60. OncoDNA Recent Developments
Table 61. Sapience Therapeutics Basic Information List
Table 62. Sapience Therapeutics Description and Business Overview
Table 63. Sapience Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Sapience Therapeutics (2019-2024)
Table 65. Sapience Therapeutics Recent Developments
Table 66. Caris Life Sciences Basic Information List
Table 67. Caris Life Sciences Description and Business Overview
Table 68. Caris Life Sciences Molecular Cancer Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Caris Life Sciences (2019-2024)
Table 70. Caris Life Sciences Recent Developments
Table 71. Hera Biolabs Basic Information List
Table 72. Hera Biolabs Description and Business Overview
Table 73. Hera Biolabs Molecular Cancer Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Hera Biolabs (2019-2024)
Table 75. Hera Biolabs Recent Developments
Table 76. CV6 Therapeutics Basic Information List
Table 77. CV6 Therapeutics Description and Business Overview
Table 78. CV6 Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of CV6 Therapeutics (2019-2024)
Table 80. CV6 Therapeutics Recent Developments
Table 81. Carrick Therapeutics Basic Information List
Table 82. Carrick Therapeutics Description and Business Overview
Table 83. Carrick Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
Table 84. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Carrick Therapeutics (2019-2024)
Table 85. Carrick Therapeutics Recent Developments
Table 86. Foundation Medicine Basic Information List
Table 87. Foundation Medicine Description and Business Overview
Table 88. Foundation Medicine Molecular Cancer Therapeutics Products, Services and Solutions
Table 89. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Foundation Medicine (2019-2024)
Table 90. Foundation Medicine Recent Developments
Table 91. Cybrexa Therapeutics Basic Information List
Table 92. Cybrexa Therapeutics Description and Business Overview
Table 93. Cybrexa Therapeutics Molecular Cancer Therapeutics Products, Services and Solutions
Table 94. Revenue (US$ Million) in Molecular Cancer Therapeutics Business of Cybrexa Therapeutics (2019-2024)
Table 95. Cybrexa Therapeutics Recent Developments
Table 96. Key Raw Materials Lists
Table 97. Raw Materials Key Suppliers Lists
Table 98. Molecular Cancer Therapeutics Downstream Customers
Table 99. Molecular Cancer Therapeutics Distributors List
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
Table 103. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Molecular Cancer Therapeutics Product Picture
Figure 2. Global Molecular Cancer Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Molecular Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Molecular Cancer Therapeutics Report Years Considered
Figure 5. Global Molecular Cancer Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Molecular Cancer Therapeutics Revenue in 2023
Figure 7. Molecular Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Monoclonal Antibodies Picture
Figure 9. Small Molecule Inhibitors Picture
Figure 10. Global Molecular Cancer Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Molecular Cancer Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Lung Cancer
Figure 13. Product Picture of Breast Cancer
Figure 14. Product Picture of Colorectal Cancer
Figure 15. Product Picture of Leukemia
Figure 16. Product Picture of Others
Figure 17. Global Molecular Cancer Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Molecular Cancer Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Molecular Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Molecular Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Molecular Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Molecular Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Molecular Cancer Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Molecular Cancer Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Molecular Cancer Therapeutics Sales Value (%), (2019-2030)
Figure 30. United States Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 36. China Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 38. China Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 48. India Molecular Cancer Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Molecular Cancer Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 50. India Molecular Cancer Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 51. Molecular Cancer Therapeutics Industrial Chain
Figure 52. Molecular Cancer Therapeutics Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
